Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment

Asia-Pacific Journal of Clinical Oncology

Volumn 13, Issue 5, 2017, Pages e189-e194

  Lin, Gui Nan ^a   Peng, Jie Wen ^a   Liu, Pan Pan ^b   Liu, Dong Ying ^a   Xiao, Jian Jun ^a   Chen, Xiao Qin ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

epidermal growth factor receptor; neutrophil to lymphocyte ratio; non small cell lung cancer; prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; BLOOD; LUNG TUMOR; LYMPHOCYTE; NEUTROPHIL; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL ANALYSIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; NEUTROPHILS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85032375931     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12273     Document Type: Article

References (21)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11–30.
2. Hotta K, Fujiwara Y, Kiura K et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thoracic Oncol 2007; 2: 402–407.
3. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–957.
4. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomized, phase 3 study. Lancet Oncol 2011; 12: 735–742.
5. Sequist LV, Yang JCH, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327–3334.
6. Colotta F, Allavena P, Sica A et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073–1081.
7. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436–444.
8. Yao Y, Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother 2013; 62: 471–479.
9. Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res 2011; 31: 2995–2998.
10. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011; 104: 1288–1295.
11. An X, Ding PR, Li YH et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010; 15: 516–522.
12. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.
13. Pinato DJ, Mauri FA, Ramakrishnan R et al. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol 2012; 7: 587–594.
14. Kao SC, Pavlakis N, Harvie R et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010; 16: 5805–5813.
15. Lee Y, Kim SH, Han JY et al. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J Cancer Res Clin Oncol 2012; 138: 2009–2016.
16. Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer 2013; 13: 158.
17. Pinato DJ, Shiner RJ, Seck MJ et al. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer 2014; 110: 1930–1935.
18. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? J Lancet 2001; 357: 539–545.
19. Canna K, McArdle PA, McMillan DC et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005; 92: 651–654.
20. Petrie HT, Klassen LW, Kay HD. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 1985; 134: 230–234.
21. Shau HY, Kim A. Suppression of lymphokine-activated killer induction by neutrophils. J Immunol 1988; 141: 4395–4402.